Hutchmed Receives Conditional Approval for Tazverik as Follicular Lymphoma Treatment in China

MT Newswires Live2025-03-21

Hutchmed (China) (HCM) said Friday that China's National Medical Products Administration granted conditional approval for the new drug application for Tazverik as a treatment for adult patients with relapsed or refractory follicular lymphoma.

The company said results of a phase 2 trial supported the conditional approval, with Tazverik demonstrating "promising efficacy." Hutchmed said the ongoing SYMPHONY-1 study is intended to be the confirmatory trial to validate Tazverik's clinical benefits.

Hutchmed is in charge of Tazverik's development and commercialization in China, Hong Kong, Macau and Taiwan, while Epizyme is the marketing authorization holder in China, according to the statement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2521077364?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-21 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521077364","market":"sh","top_or_hot":-1,"title":"Hutchmed Receives Conditional Approval for Tazverik as Follicular Lymphoma Treatment in China","media":"MT Newswires Live","content":"<html><body><p> Hutchmed (China) (HCM) said Friday that China's National Medical Products Administration granted conditional approval for the new drug application for Tazverik as a treatment for adult patients with relapsed or refractory follicular lymphoma.</p><p>The company said results of a phase 2 trial supported the conditional approval, with Tazverik demonstrating \"promising efficacy.\" Hutchmed said the ongoing <a href=\"https://laohu8.com/S/SIHL.UK\">SYMPHONY</a>-1 study is intended to be the confirmatory trial to validate Tazverik's clinical benefits.</p><p>Hutchmed is in charge of Tazverik's development and commercialization in China, Hong Kong, Macau and Taiwan, while Epizyme is the marketing authorization holder in China, according to the statement.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hutchmed Receives Conditional Approval for Tazverik as Follicular Lymphoma Treatment in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHutchmed Receives Conditional Approval for Tazverik as Follicular Lymphoma Treatment in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-21 19:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hutchmed (China) (HCM) said Friday that China's National Medical Products Administration granted conditional approval for the new drug application for Tazverik as a treatment for adult patients with relapsed or refractory follicular lymphoma.</p><p>The company said results of a phase 2 trial supported the conditional approval, with Tazverik demonstrating \"promising efficacy.\" Hutchmed said the ongoing <a href=\"https://laohu8.com/S/SIHL.UK\">SYMPHONY</a>-1 study is intended to be the confirmatory trial to validate Tazverik's clinical benefits.</p><p>Hutchmed is in charge of Tazverik's development and commercialization in China, Hong Kong, Macau and Taiwan, while Epizyme is the marketing authorization holder in China, according to the statement.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2521077364","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521077364","pubTimestamp":1742556531,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hutchmed   said Friday that China's National Medical Products Administration granted conditional approval for the new drug application for Tazverik as a treatment for adult patients with relapsed or refractory follicular lymphoma.The company said results of a phase 2 trial supported the conditional approval, with Tazverik demonstrating \"promising efficacy.\" Hutchmed said the ongoing SYMPHONY-1 study is intended to be the confirmatory trial to validate Tazverik's clinical benefits.Hutchmed is in charge of Tazverik's development and commercialization in China, Hong Kong, Macau and Taiwan, while Epizyme is the marketing authorization holder in China, according to the statement.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1587":"次新股","BK1588":"回港中概股","00013":"和黄医药","BK4007":"制药","BK4531":"中概回港概念","HCM":"和黄医药","BK1191":"制药"},"translate_title":"和黄医药在中国获得Tazverik治疗滤泡性淋巴瘤的有条件批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCM":0.9,"00013":1},"content_text":"Hutchmed (China) (HCM) said Friday that China's National Medical Products Administration granted conditional approval for the new drug application for Tazverik as a treatment for adult patients with relapsed or refractory follicular lymphoma.The company said results of a phase 2 trial supported the conditional approval, with Tazverik demonstrating \"promising efficacy.\" Hutchmed said the ongoing SYMPHONY-1 study is intended to be the confirmatory trial to validate Tazverik's clinical benefits.Hutchmed is in charge of Tazverik's development and commercialization in China, Hong Kong, Macau and Taiwan, while Epizyme is the marketing authorization holder in China, according to the statement.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2521077364","isCrawlerRequest":true}